Omalizumab in children with severe allergic disease: a case series
ConclusionsOmalizumab appears to be an excellent therapeutic option in children with inadequately controlled severe allergic asthma, allergic rhinitis and rhinosinusitis, with or without food allergy.
Source: Italian Journal of Pediatrics - Category: Pediatrics Source Type: research
More News: Allergy | Allergy & Immunology | Anaphylactic Shock | Asthma | Children | Clinical Trials | Diets | Emergency Medicine | Epidemics | Epidemiology | Food Allergy | Hay Fever | Hives | Immunotherapy | International Medicine & Public Health | Italy Health | Nutrition | Pediatrics | Xolair